Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 35

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 35
---
 | -     |     | -            |     | -                                   |     | X                      |
| Patrick Zenner, M.B.A.           |     | X     |     | X            |     | Chair                               |     | -                      |

(1) Dr. de Silva resigned from the Science and Technology Committee and joined the Compensation Committee on March 27, 2025.

(2) Dr. Kalayoglu joined the Nominating and Corporate Governance Committee on March 27, 2025.

#### Audit Committee
Our Audit Committee’s responsibilities include:

• appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;

• overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from such firm;

• reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures;

• monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics;

• discussing our risk management policies and conducting regular risk assessments related to all matters affecting the enterprise, including cybersecurity, and receives periodic reports on our cybersecurity risks and activities;

• establishing policies regarding hiring employees from the independent registered public accounting firm and procedures for the receipt and retention of accounting related complaints and concerns;

<div align='center'>20</div>

• meeting independently with our internal auditing staff, if any, independent registered public accounting firm and management;

• reviewing and approving or ratifying any related person transactions; and

• preparing the audit committee report required by the SEC rules (which is included on page 13of this proxy statement).

The Audit Committee charter is available on the “Corporate Governance” section of the “Investors” page of our website at www.cartesiantherapeutics.com. The members of the Audit Committee are Timothy C. Barabe, M.B.A., Carrie S. Cox, Nishan de Silva, M.D., M.B.A, and Patrick Zenner, M.B.A. Mr. Barabe serves as the Chairman of the Audit Committee. Our Board has affirmatively determined that each of Mr. Barabe, Ms. Cox, Dr. de Silva and Mr. Zenner is independent for purposes of serving on an audit committee under Rule 10A-3 promulgated under the Exchange Act and the Nasdaq rules. The members of our Audit Committee meet the requirements for financial literacy under the applicable rules of Nasdaq. Our Board has determined that each of Mr. Barabe and Mr. Zen